The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 49 条
  • [1] Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole
    Martinez-Melendez, Adrian
    Tijerina-Rodriguez, Laura
    Collins, Nathania
    Baines, Simon D.
    Morfin-Otero, Rayo
    Camacho-Ortiz, Adrian
    Villarreal-Trevino, Licet
    Garza-Gonzalez, Elvira
    MICROBIAL DRUG RESISTANCE, 2021, 27 (12) : 1672 - 1676
  • [2] Oral fidaxomicin versus vancomycin for Clostridioides difficile infection
    Long, Brit
    Gottlieb, Michael
    ACADEMIC EMERGENCY MEDICINE, 2022, 29 (12) : 1506 - 1507
  • [3] A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection
    Diaz-Pollan, Beatriz
    Molina, Sergio Carrasco
    Marcelo, Cristina
    Grela, Alejandro de Gea
    Martinez-Martin, Patricia
    Jimenez-Gonzalez, Maria
    Ramos, Francisco Moreno
    Mora-Rillo, Marta
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [4] Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
    Whitney, Laura
    Nesnas, John
    Planche, Timothy
    ANTIBIOTICS-BASEL, 2023, 12 (01):
  • [5] The Clinical Effectiveness of Fidaxomicin Compared to Vancomycin in the Treatment of Clostridioides difficile Infection, A Single-Center Real-World Experience
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    McDermott, Laura A.
    Walk, Seth T.
    Kent, David M.
    Snydman, David R.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (06) : 1501 - 1509
  • [6] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
    Jiang, Yiling
    Sarpong, Eric M.
    Sears, Pamela
    Obi, Engels N.
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) : 111 - 126
  • [7] The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
    Hall, Ronald G., II
    Cole, Travis J.
    Shaw, Chip
    Alvarez, Carlos A.
    ANTIBIOTICS-BASEL, 2022, 11 (03):
  • [8] Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile
    Turner, Nicholas A.
    Warren, Bobby G.
    Gergen-Teague, Maria F.
    Addison, Rachel M.
    Addison, Bechtler
    Rutala, William A.
    Weber, David J.
    Sexton, Daniel J.
    Anderson, Deverick J.
    CLINICAL INFECTIOUS DISEASES, 2022, 74 (04) : 648 - 656
  • [9] Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides difficile Infection: A Single-Center Study
    Alsoubani, Majd
    Chow, Jennifer K.
    Rodday, Angie Mae
    Kent, David
    Snydman, David R.
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (01):
  • [10] The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
    Seekatz, Anna Maria
    Safdar, Nasia
    Khanna, Sahil
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15